ABOUT THE BLOG

ADAM J. FEIN, PH.D.
OUR READERS
HOW DRUG CHANNELS BENEFITS OUR READERS
SITE TRAFFIC


The $300 billion United States pharmaceutical industry grows ever larger and more complicated by the day. A new generation of specialty drugs is launching, brand-name drugs are facing greater generic competition, channels and payers are consolidating, and the government’s role in the industry keeps evolving.

To remain competitive, it has never been more crucial to master the fundamental commercial industry concepts, understand the rapidly evolving relationships among the players in the drug channels landscape, and stay current with industry trends.

Since 2006, the Drug Channels website has been helping our thousands of readers make sense of pharmaceutical economics and the drug distribution system. We deliver timely analysis and provocative, widely regarded opinions on the highly dynamic healthcare system. We also provide readers with original analyses of public data and help readers to think critically about the viewpoints presented in other media.

Drug Channels is the ultimate source for such topics as:
  • Pharmacy Economics and Prescription Profits
  • Pharmaceutical reimbursement
  • Business strategies of key market participants, including manufacturers, pharmacies, pharmacy benefit managers (PBMs), third-party payers, and wholesalers
  • Industry evolution and trends
  • The fast-growing specialty drug market
  • Healthcare reform and policy
  • Legal aspects of the pharmaceutical supply chain

ADAM J. FEIN, PH.D.

Drug Channels was created and is written by Adam J. Fein, Ph.D., president of Pembroke Consulting, Inc., and CEO of Drug Channels Institute. Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. Top manufacturers call on Dr. Fein’s insights and judgment, to create successful commercial strategies and make better strategic decisions in our evolving healthcare environment. Click here to read more about Dr. Fein’s industry presence.

Dr. Fein excels at unlocking and explaining complex business and economic issues with humor and an accessible, straightforward style, making Drug Channels a popular and authoritative destination for both industry insiders and outsiders. Drug Channels has been cited in such media outlets as The Wall Street Journal and Drug Benefit News, in academic research papers, and across other industry websites.

OUR READERS

A leader in pharmaceutical economic analysis, Drug Channels has a loyal following of engaged readers. Drug Channels attracts a large, unique, diverse audience throughout the pharmaceutical and healthcare industries.

Our readers’ backgrounds reflect the many diverse topics that Drug Channels reports and analyzes. We offer free subscriptions via email, RSS feed, or Twitter. As of August 2014, Drug Channels had nearly 10,000 subscribers via these methods. All articles are also shared with the more than 1,500 people on Dr. Fein’s personal LinkedIn account.

On our twitter page, @DrugChannels, we provide ongoing news and opinions about drug distribution, pharmaceutical economics, reimbursement, payers, current events, and more.

People at the largest and most influential healthcare companies regularly read Drug Channels. View of a list of companies that visited Drug Channels. Many key healthcare industries are represented in our readership.

[Click to Enlarge]


HOW DRUG CHANNELS BENEFITS OUR READERS
Drug Channels is one of my must-follow resources for knowledgeable insight into events that are shaping the future of our industry. Dr. Fein's ability to find the real meaning behind the headlines is refreshing and invaluable.
Bill Martin, VP Pharma Strategies and Account Management, Express Scripts

Drug Channels is a terrific (and entertaining) resource to stay up to date on complex issues related to the pharmaceutical channel. The mix of pop culture references with deep insight into current events makes the articles a must read.
Keith Wagner, Pharm.D., MBA, Director, Trade/Specialty Accounts, Lilly USA

Great informative and timely information with a wit and humor that reminds us that serious issues all need to be tempered with a sense of levity.
Scott A. Miller, Pharm.D., Director, Clinical Strategic Initiatives, Walgreens

"Adam is a master at presenting the facts, sharing his insights and leaving the door open for contemplation."
Laura White, R.Ph., Strategic Consultant, Humana, Inc.

"Drug Channels should be required reading for pharmacists and other healthcare professionals!"
Doug Wurtzbacher, Pharm.D., Ph.D., Pharmacy Sourcing Manager, Premier Health

"Drug Channels is my best source of current, up-to-date information about current events affecting pharmacies, wholesalers, and PBMs. I constantly use the information in my teaching, research, and consulting."
Norman V. Carroll, R.Ph, Ph.D., Professor of Pharmacoeconomics and Health Outcomes, School of Pharmacy, Virginia Commonwealth University

SITE TRAFFIC

Drug Channels' site traffic is growing by 25% to 30% per year. Traffic averages more than 50,000 monthly page views. The chart below shows the growth in annual page views as recorded by Statcounter, our web traffic provider.

[Click to Enlarge]


Click here to view current summary web traffic data for Drug Channels.

Learn about advertising on Drug Channels and connecting with our community.